PEB: Anticipated Medicare re-coverage and capital raise position for growth in cancer diagnostics

About this update from Pacific Edge Limited

Patented Cxbladder urine tests are supported by strong clinical evidence and are positioned for significant market growth, pending anticipated Medicare re-coverage. A NZ$24 million capital raise aims to support ongoing operations, innovation, and expansion, with cost-saving measures reducing cash burn and APAC operations trending toward profitability.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Pacific Edge Limited